for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UBI Pharma Inc

6562.TWO

Latest Trade

86.80TWD

Change

-0.50(-0.57%)

Volume

428,261

Today's Range

86.60

 - 

87.70

52 Week Range

37.50

 - 

300.00

As of on the Gre Tai Security Market ∙ Minimum 15 minute delay

Pricing

Previous Close
87.30
Open
87.00
Volume
428,261
3M AVG Volume
0.36
Today's High
87.70
Today's Low
86.60
52 Week High
300.00
52 Week Low
37.50
Shares Out (MIL)
142.39
Market Cap (MIL)
1,637.52
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

UBI Pharma gets patent in EU

UBI Pharma passes U.S FDA review of clinical trial in human for anticancer drug

UBI Pharma to pay 2015 dividend on Sep. 30

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About UBI Pharma Inc

UBI Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services. The protein drug product line includes erythropoietin (UB-851) biosimilar drugs, innovative long-acting erythropoietin (UB-852), innovative long-acting granular ball community stimulating hormone (UB-853), and others used to treat anemia, neutropenia. The small molecule new drug product line includes B-Raf kinase inhibitor (UB-941) for the treatment of melanoma. The special scientific name drug product line includes tablets Olanzapine and Nevirapin for the treatment of schizophrenia and AIDS, and injections Granisetronl and Meropenen for the treatment of bacterial infections. It sells products in the domestic market and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.45, Guangfu North Road

303

Taiwan

+886.35.977676

Executive Leadership

Qixiang Chen

Chairman of the Board, General Manager

Jiawei Hong

Finance Manager

Wenjun Peng

Chief Operating Officer-Private Product

Yingyun Fan

Deputy General Manager-Administration Center, Director

Yanning Guo

Deputy General Manager-Operation Development & Technology Service Center, Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
3.74
Price To Book (MRQ)
2.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
289.72
LT Debt To Equity (MRQ)
259.26
Return on Investment (TTM)
-13.12
Return on Equity (TTM)
-11.37

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up